We came across a bullish thesis on UnitedHealth Group Incorporated (UNH) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on UNH. UnitedHealth Group Incorporated (UNH)’s share was trading at $524.99 as of Jan 21st. UNH’s trailing and forward P/E were 33.85 and 17.64 respectively according to Yahoo Finance.
Valeri Potapova/Shutterstock.com
UnitedHealth Group (UNH) enters 2025 with a strong track record and a clear strategy for continued growth in the healthcare sector. Despite challenges in the fourth quarter of 2024, where the company’s medical loss ratio (MLR) slightly exceeded expectations, UNH continues to impress with its resilient business model, innovative use of technology, and a focus on optimizing care delivery. The company reported earnings per share (EPS) of $6.81, exceeding estimates, despite higher-than-expected costs from seasonal factors like flu and RSV, which are typically prevalent in the fourth quarter. Despite these headwinds, UNH’s multi-segment approach demonstrated strong performance across its core operations.
Optum Health’s restructuring, focusing on streamlining its services and divesting non-core assets, aligns with the company’s long-term goals of becoming a more efficient healthcare services provider. Additionally, UNH is heavily investing in technology, particularly AI and automation, to enhance operational efficiency, which will be fully implemented by 2025. This technological integration is set to support more efficient service delivery and cost management. In Medicare Advantage (MA), high retention rates and the return of former members highlight UNH’s competitive edge, along with improved coding accuracy and health modeling, ensuring more predictable costs.
The company faced significant challenges in 2024, including the $6 billion headwind from Medical Cost Ratios (MCR) and the impact of the Inflation Reduction Act (IRA) on high-cost medications. However, UnitedHealth’s proactive measures, such as strategic pricing adjustments and ongoing investments in MA, have positioned the company to navigate regulatory and market pressures effectively. Looking ahead to 2025, UNH plans to address these challenges by focusing on regulatory adjustments in MA, continuing to scale AI-driven models, and driving operational efficiencies across both its commercial and Medicare businesses.
Financially, UnitedHealth is projecting strong revenue growth, with 2025 revenues expected to reach $453.2 billion, a 13.2% increase from 2024. EBITDA margins are forecasted to remain robust at 9.8%, with EBIT margins stabilizing at 8.8%. Over the next several years, UNH’s revenue is expected to exceed $600 billion by 2029. The stock is currently trading at a forward price-to-earnings (P/E) ratio of 17.1x, in line with the sector average, while its enterprise value-to-EBITDA ratio of 10.6x underscores its market-leading position. Free cash flow yield is projected to rise to 6.1% in 2025, driven by disciplined capital allocation.
UnitedHealth continues to prioritize shareholder returns, with dividends per share expected to grow by 15% in 2025, alongside significant share buybacks. The company’s consistent long-term growth, strategic outlook, and commitment to delivering value make it a strong contender in the healthcare sector, with a price target of $674, reflecting a 29% potential upside from its current share price.
UnitedHealth Group Incorporated (UNH) is on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 112 hedge fund portfolios held UNH at the end of the third quarter which was 114 in the previous quarter. While we acknowledge the risk and potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than UNH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.